Tirzepatide vs. Semaglutide: Which GLP-1 Is Best for Weight Loss?
Tirzepatide produces greater average weight loss than semaglutide in head-to-head and real-world studies. The SURMOUNT-5 trial showed tirzepatide 15 mg achieved approximately 20.2% weight reduction versus semaglutide 2.4 mg at 13.7%. However, the "best" choice depends on your individual priorities—semaglutide has broader cardiovascular and kidney protection data, while tirzepatide offers superior weight loss efficacy and better treatment persistence.
How They Work Differently
Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor agonist—it activates two hormone pathways that regulate appetite and blood sugar. This dual mechanism is why tirzepatide typically produces greater weight loss than single-target medications.
Semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist that mimics one natural hormone to reduce appetite and slow stomach emptying. It has a longer track record in clinical use and broader FDA approvals for cardiovascular and kidney protection.
Head-to-Head: What the Research Shows
| Outcome | Tirzepatide (15 mg) | Semaglutide (2.4 mg) | Source |
|---|---|---|---|
| Average weight loss | 20.2% | 13.7% | SURMOUNT-5 trial |
| ≥15% weight loss | 56.8% | 40.7% | Real-world study (n=511) |
| ≥20% weight loss | 39.0% | 22.1% | Real-world study |
| 12-month persistence | 67% | 13% | Retrospective cohort |
| GI side effects | 28.5% | 50.7% | Real-world study |
A retrospective cohort of non-diabetic adults with obesity found tirzepatide produced 37.1 lbs mean weight loss versus 20.2 lbs for semaglutide at 12 months (p<0.001). The same study found insurance/cost barriers caused discontinuation in 47% of semaglutide patients versus 21% of tirzepatide patients.
When Semaglutide May Be the Better Choice
Despite tirzepatide's superior weight loss numbers, semaglutide has distinct advantages:
Cardiovascular protection is proven. Semaglutide is the only weight loss medication proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients with known heart disease and obesity. If you have existing cardiovascular disease, this evidence is clinically significant.
Broader FDA approvals. Wegovy is approved for cardiovascular risk reduction and MASH (metabolic dysfunction-associated steatohepatitis), while Zepbound's additional approval is for obstructive sleep apnea.
Lower cost through Medicare. The Medicare GLP-1 Bridge program covers semaglutide (Wegovy) at $50 per month through the end of 2027. Zepbound is also available through this program, but semaglutide has been the primary focus.
How to Get These Medications
Zepbound (tirzepatide) is available through LillyDirect self-pay at $299–$499 per month depending on dose, with the KwikPen now available at major pharmacies nationwide. Insurance coverage for weight loss is limited—about 19% of large firms cover GLP-1 drugs for weight loss in 2025.
Wegovy (semaglutide) is available through NovoCare Pharmacy, telehealth partners like Hims & Hers, and Amazon Pharmacy. Cash-pay pricing starts at $149/month** for the oral pill and **$199/month for injectables through some programs. The oral Wegovy pill is the first FDA-approved oral GLP-1 for weight management.
Side Effects to Expect
Both medications cause similar gastrointestinal side effects: nausea, diarrhea, vomiting, constipation, and abdominal pain. The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, and fatigue. Wegovy's side effects include nausea, diarrhea, vomiting, constipation, headache, fatigue, and upset stomach.
Important warning: Both medications may cause thyroid tumors, pancreatitis, gallbladder problems, and kidney issues from dehydration. Do not use either if you or your family have a history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
Which One Is Right for You?
| Your Priority | Better Choice |
|---|---|
| Maximum weight loss | Tirzepatide |
| Heart disease protection | Semaglutide |
| Lower monthly cost | Semaglutide (Medicare) |
| Oral pill option | Semaglutide (Wegovy pill) |
| Better tolerability | Tirzepatide |
| Longer safety track record | Semaglutide |
The bottom line: Tirzepatide wins on weight loss numbers, but semaglutide has unique cardiovascular benefits and better affordability through Medicare. The right choice depends on your medical history, insurance coverage, and weight loss goals. Always consult a licensed healthcare provider before starting either medication.
